Table of Contents

    Topic review

    Whole Ovary Cryopreservation and Transplantation

    View times: 78
    Submitted by: Camille Hossay


    The aim of this systematic review is to shed light on the challenges of whole ovary cryopreservation and transplantation and to summarize the solutions that have been proposed so far in animal experiments and humans in order to stimulate further research in the field.

    1. Introduction

    Ovarian tissue cryopreservation and transplantation is the only fertility preservation option that enables both restoration of fertility and resumption of ovarian endocrine function, avoiding the morbidity associated with premature menopause. It is also the only technique available to prepubertal patients and those whose treatment cannot be delayed for life-threatening reasons. Ovarian tissue cryopreservation can be done in two different ways, either as ovarian cortical fragments or as a whole organ with its vascular pedicle. Although use of cortical strips is the only procedure that has been approved by the American Society for Reproductive Medicine, it is fraught with drawbacks, the major one being serious follicle loss occurring after avascular transplantation due to prolonged warm ischemia. Whole ovary cryopreservation involves vascular transplantation, which could theoretically counteract the latter phenomenon and markedly improve follicle survival. In theory, this technique should maintain endocrine and reproductive functions much longer than grafting of ovarian cortical fragments. However, this procedure includes a number of critical steps related to (A) the level of surgical expertise required to accomplish retrieval of a whole ovary with its vascular pedicle, (B) the choice of cryopreservation technique for freezing of the intact organ, and (C) successful execution of functional vascular reanastomosis upon thawing. The aim of this systematic review is to shed light on these challenges and summarize solutions that have been proposed so far in animal experiments and humans in the field of whole ovary cryopreservation and transplantation.

    2. Methodology

    This systematic review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines using the MEDLINE database (PubMed) [1] (Figure 1). The following keywords were entered into the database: whole ovary, cryopreservation, transplantation. Out of 140 records, only peer-reviewed research articles focusing on the subject and written in English were taken into account for eligibility assessment (n = 69). Among studies performed on animal models, the following criteria led to the exclusion of 16 papers: (i) cryopreservation protocols for small animal models; (ii) transplantation of fresh whole ovaries; (iii) avascular transplantation. All studies using whole human ovaries were included, resulting in a total of 53 papers.

    Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart.

    3. Challenges and Solutions

    Although whole ovary cryopreservation and transplantation has yielded several live births in large animals [2][3][4], the technique involves a number of critical steps. The three main hurdles of whole ovary cryopreservation and transplantation are linked to (A) the surgical skills required to accomplish retrieval of a whole ovary with its vascular pedicle, (B) the cryopreservation technique adopted for freezing of the intact organ, and (C) successful execution of functional vascular reanastomosis upon thawing.

    3.1. Whole ovary removal

    In order to successfully harvest the entire ovary with its vascular pedicle for cryopreservation and future vascular reimplantation, great care must be taken when dissecting the ovarian vessels within the infundibulopelvic ligament. Indeed, the ovarian pedicle must be long enough (≥5 cm in humans) to allow processing of the graft and ensure perfect suture of donor vessels to recipient vessels of similar diameter [5][6]. Another crucial aspect is shortening the ischemic interval between ovary removal and cryopreservation as much as possible to avoid injury to ovarian cells [5][7][8][9]. For this reason, in the majority of studies, whole ovary removal is performed by laparotomy. However, some authors have demonstrated the feasibility of the procedure by laparoscopic surgery in sheep [10][11][12][13] and humans [5][14], despite the very twisted appearance of the ovarian vessels.

    3.2. Freezing of a whole ovary

    3.2.1. Freezing challenges

    Developing a successful cryopreservation protocol for large organs like whole ovaries is extremely challenging [15]. Unfortunately, the success rate of freezing is inversely proportional to the complexity of the biological system being cryopreserved [16]. Numerous issues are associated with freezing and thawing of a whole ovary while preserving its viability upon thawing, including heat and mass transfer, poor heat transfer between the core and periphery of the organ, and adequate distribution of the cryoprotectant throughout the organ to prevent ice formation [17][18][19][20][21][22].

    A preliminary in vitro study utilizing intact porcine ovaries demonstrated the beneficial effect of cryoprotectant use on the preservation of the ultrastructural integrity of primordial follicles [23]. Two further studies conducted on sheep ovaries underlined the protective impact of adding cryoprotectant to the freezing medium, compared to using a simple freezing medium composed of Ringer’s solution without any cryoprotective agents [24][25]. Wallin et al. (2009) used propanediol [24], while Milenkovic et al. (2011a) opted for dimethyl sulfoxide (DMSO) as cryoprotectants [25]. Viability was assessed the same way in both studies and the results were similar. Briefly, the whole ovary was placed in a perfusion tray after thawing and stimulated with an adenylate cyclase stimulator (forskolin). Cyclic adenosine monophosphate (cAMP) and hormone levels were measured after stimulation and no significant difference was identified between groups with or without cryoprotectant. After perfusion, cells were isolated and cultured. Addition of human chorionic gonadotropin (hCG) to cell cultures resulted in higher progesterone levels in the group cryopreserved with cryoprotectant than the group cryopreserved without cryoprotectant. Histological assessment showed well preserved tissue architecture, with the presence of small follicles in all groups immediately after thawing. However, the ovarian architecture of ovaries frozen without cryoprotectant became disrupted, with signs of edema, disorganized stroma and shrunken follicles after perfusion, emphasizing the benefits of adding cryoprotectant to the freezing medium.

    Optimal distribution of cryoprotectant throughout the organ and its vascular network is of paramount importance to avoid ice formation in intracellular and extracellular locations, particularly in blood vessels [18][26][27][28]. Intravascular ice formation irreversibly disrupts the endothelial cell layer, resulting in thrombotic events after transplantation of a frozen-thawed whole ovary [18][26][28][29][30][31]. Indeed, the large volume and complexity of a whole organ somewhat hamper cryoprotectant diffusion, making it difficult to obtain even distribution within the organ without inducing unacceptable levels of toxicity caused by high doses of cryoprotectant [19][32][33][34][35][36]. Gerritse et al. (2011) stressed the importance of associating perfusion of the ovarian pedicle with submersion of the bovine ovary using a cryoprotective solution to confer the highest degree of protection [37]. Another group investigated whether in vivo perfusion of the ovarian artery before removal of the ovine ovary could achieve optimal cryoprotectant distribution throughout the organ, but found that only 10% of the ovarian tissue was actually perfused. They concluded that perfusion should be performed in vitro, as described above [38].

    Various studies have demonstrated a deleterious effect of both perfusion and cryopreservation on the ovarian vasculature, especially on the microvasculature within the ovarian medulla [18][24][34][39][40][41]. This could lead to capillary microthrombi arising from the ovarian medulla, remote from the anastomotic site, causing local ischemia. This process might be responsible for the poor follicle outcomes reported in several animal studies after vascular transplantation of whole ovaries, despite maintaining vascular patency of the anastomotic site [3][31][41]. An in vitro study performed with intact sheep ovaries demonstrated that cryopreservation significantly increased endothelial cell disruption and smooth muscle damage, but that adding the antiapoptotic agent sphingosine-1-phosphate to the cryopreservation medium (composed of 1.5 M DMSO) did not improve ovarian or vascular tissue viability following cryopreservation [42]. The authors concluded that cell loss was either due to necrosis caused by intracellular ice formation and osmotic stress, or that they might have targeted the wrong apoptotic pathway.

    To further confirm that perfusion alone and perfusion associated with freezing have deleterious effects on endothelial cell function compared to unperfused fresh controls, the same team studied a number of endothelial cell-related genes in the medulla and the pedicle [41]. Like expression of endothelial nitric oxide synthase, cryopreservation did not affect expression of endothelin-1 in the pedicle, but it was significantly downregulated in the medulla compared to perfusion alone. This suggests that small medullary vessels are more sensitive to the effects of cryopreservation, limiting their reactivity to vascular tone. On the other hand, expression of endothelin-2 was significantly upregulated in the pedicle after perfusion, suggesting that hypoxic conditions may have been created there during perfusion. However, since hypoxia stimulates endothelins, including endothelin-1 and -2, the authors could not explain why endothelin-1 did not follow the same pattern. Regarding cellular apoptosis, upregulation of proapoptotic Bcl-2-associated X protein (BAX) expression and downregulation of antiapoptotic Bcl-2 expression in response to perfusion and freezing suggested detrimental effects of both of these processes on cell survival. Interestingly, caspase-6 expression in the medulla was downregulated after perfusion, indicating that final execution of cell death may be suppressed within the medulla, despite potential upregulation of the apoptotic pathway by BAX, but the reason for this remains unknown. Expression of thrombospondin-1 was found to be downregulated in the medulla and pedicle after perfusion. According to the authors, downregulation of thrombospondin-1 expression may imply that wound repair mechanisms are recruited due to perfusion. They also concluded that both perfusion alone and in combination with freezing had a deleterious impact on endothelial cell function [41].

    3.2.2. Freezing solutions

    Considering all the issues involved in cryopreserving a whole organ, animal models used to investigate freezing protocols should have ovaries similar to humans in terms of size, architecture and ovulation patterns, with comparable follicle distribution within the cortex [35]. Porcine, ovine and bovine ovaries may be considered appropriate models [35][43], whose characteristics are summarized in Table 1. Three different freezing techniques have been developed over time: slow freezing, vitrification and directional freezing. The two main freezing procedures used for whole ovary cryopreservation are slow freezing and vitrification, but directional freezing is gaining ground thanks to recent encouraging results. The advantages/disadvantages of the three different ways of cryopreserving a whole ovary, are summarized in Table 2.

    Table 1. Ovarian characteristics in large animal models compared to the human ovary


    Ovarian volume (mean ± SD)

    Tissue architecture compared to the human ovary

    Ovulation pattern

    Cycle length (days)


    6.5 ± 2.9 cm3 [43]

    Not applicable




    14.3 ± 5.7 cm3 [35]

    Similar to human

    Mono-, diovulatory



    7.3 ± 2.2 cm3 [35]

    Less fibrous




    1.0 ± 0.4 cm3 [35]

    Similar to human

    Mono-, triovulatory

    16-17 (seasonal)

    Table 2. Comparison of different freezing techniques




    Slow freezing

    Small amounts of cryoprotectant

    Prone to intracellular ice formation

    Non-uniform cooling gradient between the core and periphery


    No crystallization, amorphous state of liquids

    Large amounts of cryoprotectant

    Directional freezing

    Controlled and uniform cooling gradient between the core and periphery

    New technique, very few studies reported in the literature

    3.3. Vascular transplantation of a whole ovary

    3.3.1. Vascular transplantation challenges

    Vascular transplantation of fresh whole ovaries has been largely successful in animal models (rats [44][45][46], rabbits [47][48][49][50][51][52][53][54][55], sheep [10][12][30][31][41][56][57][58][59][60][61][62], pigs [63][64], dogs [65] and monkeys [66][67]). Encouraging results have also been reported on transplantation of frozen-thawed whole ovaries in rats [29][68][69][70], rabbits [71] and sheep [2][3][4][11][12][13][30][31][41][72][73][74], which will be detailed further in this review. In humans, however, only fresh whole ovary transplantation has been undertaken so far [14][75][76][77], yielding one live birth to date [14].

    For a successful outcome, vascular reanastomosis needs to be carried out by an experienced surgical team, including specialists in microvascular surgery, due to the level of complexity. Indeed, the reported diameter of the human ovarian artery is around 1 mm, and the ovarian vein approximately 1.2 mm [6]. Although the ovarian vein is slightly larger, its anastomosis may be more problematic because of its thin walls and poorly defined lumen [27].

    Furthermore, selection of recipient vessels must be carefully considered to keep any vessel size discrepancy to a minimum, as sudden changes in vessel caliber cause turbulence to blood flow, which predisposes them to thrombosis [6][78][79]. Thrombosis is indeed the most common cause of anastomotic failure and is regulated by Virchow’s triad (damaged endothelial lining, hypercoagulability, turbulent blood flow).  End-to-end vascular anastomosis is the most reliable approach, with an accuracy of 96%, and should be implemented when the vessel mismatch ratio is below 1:1.5 [6][78]. If the vessel mismatch ratio is above 1:1.5, a number of microsurgical techniques may be applied to manage donor versus recipient vessel discrepancy, such as oblique cutting, fish-mouth cutting, the sleeve technique or end-to-side anastomosis [6][78][80]. The goal is to achieve optimal blood flow through the connection and reduce the risk of thrombosis. In addition, sutureless methods like adhesives, laser welding or stents may also be considered depending on the surgeon’s experience [78][81][82]. Unfortunately, there is no consensus to date on the ideal technique to resolve the problem of vessel size mismatch [6][78][80]. Moreover, these complex anastomoses often lead to higher rates of complications, so the choice of a particular technique has to be made according to each individual case [6][78][80]

    3.3.2. Vascular transplantation solutions

    The Table 3 specifically focuses on reviewing vascular transplantation of frozen-thawed whole ovaries in animals, a technique only performed in rodents and sheep so far.

    Table 3. Transplantation of cryopreserved whole ovaries in animal models



    Freezing procedure



    Outcomes of WOCT



    Wang et al. 2002b[68], Yin et al. 2003[69]

    Slow freezing

    Orthotopic, end-to-side (aorto-aortic and cava-caval)

    ≥60 days

    § 4/7 (57%) resumed estrous cycles after 12 ± 2.5 days

    § 1/7 (14.3%) conceived, but no live birth

    § Hormones (baseline vs. postgrafting): FSH ↗ (21.3 ± 6.2 vs. 9.1 ± 0.4; p<0.05); E2 ↘ (256.6 ± 61.8 vs. 416.9 ± 3.6; p<0.05)

    § Follicle counts (baseline vs. postgrafting): ↘ (p<0.01)


    Chen et al. 2006[71]

    Slow freezing

    Heterotopic (groin pocket), end-to-end (ovarian vessels to inferior epigastric vessels)

    6 months

    § 10/12 (83.3%) resumed ovarian function after 1 week

    § No IVF attempts à no pregnancy

    § Hormones (baseline vs. postgrafting): FSH ↗ (1.8 ± 0.5 vs. 15.5 ± 3.6; p<0.01); P, E2 and LH =

    § Follicle counts (baseline vs. postgrafting): ↘ (18.68 ± 3.86 vs. 13.99 ± 3.21; p<0.0001)


    Qi et al. 2008[29]

    Slow freezing

    Orthotopic, end-to-side (aorto-aortic & cava-caval)

    ≥42 days

    § 8/10 (80%) resumed estrous cycles after 14 ± 3days

    § 2/10 (20%)conceived, but no live birth

    § Hormones (baseline vs. postgrafting): E2↘  (258 6 98 pmol/l vs. 434 6 98 pmol/l)

    § Follicle counts: not mentioned


    Ding et al. 2018b[70]

    Slow freezing

    Orthotopic, end-to-side (aorto-aortic & cava-caval)


    8 months

    § 5/25 (20%) died from early postoperative complications (infection/anastomotic thrombosis)

    § 14/20 (80%) resumed estrous cycles after 14 ± 3 days

    § 4/20 (20%) conceived, yielding healthy offspring + second and third generations of rats from the initial offspring

    § Hormones:  FSH, P, E2, AMH = to sham-operated rats

    § Follicle counts: ↘ (p<0.05)



    Bedaiwy et al. 2003[11]

    Slow freezing

    Heterotopic (rectus muscle), end-to-end (ovarian vessels to inferior epigastric vessels)

    8-10 days

    § 11/11 (100%) immediate vascular patency

    § 3/11 (27%) maintained vascular patency after 8-10 days à 8/11 (73%) occluded vessels

    § Hormones (baseline vs. postgrafting):

    - Patent group: FSH = (182 ± 70.3 vs. 172 ± 42.0; p=0.84); E2 = (166 ± 50.0 vs. 163 ± 32.6; p=0.94)

    - Non-patent group: FSH ↗ (103 ± 89.7 vs. 268 ± 109; p=0.005); E2 = (199 ± 115 vs. 282 ± 132.0; p=0.25)

    § Follicle counts (patent vs. non-patent): ↘ (3.67 ± 2.08 vs. 0.250 ± 0.463; p=0.001)


    Revel et al. 2004[74], Arav et al. 2005[72], 2010[73]

    Directional freezing

    Orthotopic, end-to-end (ovarian vessels to contralateral ovarian vessels)

    6 years

    § 5/8 (62.5%) immediate vascular patency à 3/8 failure due to venous thrombosis (n=1), torn artery (n=1) and unknown reason (n=1)

    § 3/8 (37.5%) resumed P cyclicity 34 to 69 weeks after transplantation; 2/8 (25%): oocyte aspiration + embryo development up to the 8-cell stage

    § 2/8 (25%) maintained ovarian function for up to 3 years and 1/8 (12.5%) for up to 6 years

    § Hormones: not detailed

    § Follicle counts: not detailed


    Imhof et al. 2006[3]


    Slow freezing

    Orthotopic, end-to-end (ovarian vessels to contralateral ovarian vessels)

    18-19 months

    § 6/8 (75%) long-term vascular patency

    § 4/8 (50%) resumed ovarian function 6 months after transplantation and P cyclicity resumed 12-14 months postgrafting

    § 1/8 (12.5%) spontaneous pregnancy yielding healthy offspring

    § Follicle survival rate: 1.7-7.6%


    Bedaiwy and Falcone, 2007[12]

    Slow freezing

    Heterotopic (rectus muscle), ovarian vessels to inferior epigastric vessels

    8-10 days

    Successful vascular patency after 8-10 days:

    - 5/8 with end-to-end anastomosis (WOCT = 3/6; fresh = 2/2)

    - 2/6 with end-to-side anastomosis (WOCT = 1/4; fresh = 1/2)

    - 0/7 with fish-mouth anastomosis (WOCT = 0/5; fresh = 0/2)


    Grazul-Bilska et al. 2008[13]

    Slow freezing

    Heterotopic (rectus muscle), end-to-end (ovarian vessels to inferior epigastric vessels)

    5 months

    § 2/8 (25%) resumed ovarian function

    § No information on maintained vascular patency

    § 3 COCs obtained after FSH stimulation; 2 developed to metaphase II after in vitro maturation, but no fertilization

    § Hormones: only 2 ewes in whose ovarian function was restored were considered, no statistical analysis

    § Follicle counts: not mentionned


    Courbière et al. 2009[30]


    Orthotopic, end-to-end (ovarian vessels to contralateral ovarian vessels)

    12 months

    § 1/5 (20%) long-term vascular patency à 4/5 failure due to lumbo-ovarian pedicle thrombosis (n=2), arterial thrombosis (n=1) and pneumopathy (n=1) (pedicle non-analyzable)

    § 1/5 (20%) resumed ovarian function 6 months after transplantation

    § Hormones: not detailed

    § Follicle counts: total follicle loss


    Onions et al. 2009[31]

    Slow freezing

    Heterotopic (neck), end-to-side (aortic patch to carotid artery and ovarian vein to jugular vein)

    7 months

    § 7/8 (87.5%) immediate and long-term vascular patency

    (! in 1 case = freezing device malfunction à excluded from further analysis)

    § 3/7 (42.9%) resumed ovarian cyclicity

    § Follicles (pregrafting vs. postgrafting): ↘ (36.7 ± 5.7 vs. 2.3 ± 1.0; p< 0.05)


    Onions et al. 2013[41]

    Slow freezing

    Orthotopic, end-to-end (ovarian vessels to contralateral ovarian vessels)

    7 days

    § 4/4 (100%) immediate vascular patency

    § 1/4 (25%) vascular patency at degrafting à 3/4 (75%): arterial thrombosis + FMS extravasation in the medulla

    § Follicle density (pregrafting vs. postgrafting): ↘ (0.42 vs. 0.02; p< 0.001)


    Campbell et al. 2014[2]

    Slow freezing


    Orthotopic, end-to-end (ovarian vessels to contralateral ovarian vessels)

    3 months

    § 15/15 (100%) immediate vascular patency

    § 4/15 (27%) restored ovarian function within 7 weeks of transplantation

    § Follicle density within the functioning ovary (pregrafting vs. postgrafting): ↘ (2.48 ± 0.98 vs. 1.43 ± 0.10)

    Slow freezing

    Orthotopic, end-to-side (ovarian vessels to uterine vessels)

    11-23 months

    § 14/14 (100%) immediate and long-term vascular patency

    § 14/14 (100%) restored ovarian function within 3 weeks of transplantation

    § 9/14 (64%) pregnancies + 4/14 (29%) and healthy live births. One offspring gave birth to second-generation lambs

    § Follicle survival rate: 60-70%


    Torre et al. 2016[4]

    Slow freezing vs. Vitrification

    Orthotopic, end-to-end (ovarian vessels to contralateral ovarian vessels)


    3 years

    § 6/6 (100%) immediate vascular patency with slow freezing vs. 67% (4/6) with vitrification

    (1 death occurred in both groups)

    § 5/5 slow freezing + 6/6 vitrification (100%): restored hormone production

    § 1/5 (20%) pregnancy and live birth of healthy offspring in the slow-frozen group. No pregnancy in the vitrified group

    § Follicle survival rates (slow freezing vs. vitrication): 0.017% ± 0.019% vs. 0.3% ± 0.5% (p= 0.047)

    Legend: WOCT: whole ovary cryopreservation and transplantation; E2: estradiol; FSH: follicle-stimulating hormone; P: progesterone; LH: luteinizing hormone; AMH: anti-Müllerian hormone; COC: cumulus-oocyte complex; FMS: fluorescent microsphere.

    4. What has been done in humans so far?

    4.1. Fresh whole ovary transplantation

    To date, only a limited number of teams have attempted the exhausting and technically challenging feat of vascular transplantation of fresh whole ovaries in humans [14][75][76][77]. However, no attempts have yet been made to transplant a cryopreserved whole ovary in humans.

    The first grafts of fresh whole ovaries were performed to the upper arm of the patient, and two teams reported successful heterotopic transplantation before initiating sterilizing pelvic irradiation [75][76]. In the first report, the patient was suffering from Hodgkin’s lymphoma. A cavity was created in her forearm by inserting a testicular prosthesis 2 months prior to transplantation in order to prepare the grafting site [75]. The ovary was then transplanted and the ovarian vessels were branched end-to-end to the vessels from the humeral vascular bundle. The authors reported no disruption to the menstrual cycle, which remained regular for up to two years, with evidence of follicle growth in the transplanted ovary [75]. In the second report, the patient was suffering from cervical carcinoma and heterotopic autotransplantation of the ovary to the upper arm was performed in the context of radical hysterectomy prior to pelvic radiotherapy [76]. For over a year, there was evidence of regular menstrual cycles and follicle growth upon clinical examination and ultrasound. Unfortunately, local disease recurred one year later and no long-term follow-up was reported.

    A third team achieved the first successful orthotopic transplantation in a patient with Turner syndrome [77]. The transplant was retrieved from an immunologically matched donor sister through a Pfannenstiel incision. The ovarian vein was anastomosed end-to-side to the external iliac vein, and the ovarian artery was sutured end-to-end to the inferior epigastric artery by laparotomy. The ovary was fixed in its orthotopic position. Ovarian function resumed and was maintained for at least 2.5 years (follow-up duration). The patient also developed secondary sexual characteristics.

    The last published study on fresh whole ovary transplantation was in 2008 between a pair of monozygotic twins discordant for POI [14]. The donor’s ovary was laparoscopically removed and transplanted to the recipient’s ovarian vessels through a minilaparotomy incision. This was actually the first report of a healthy live birth following orthotopic vascular transplantation of a fresh whole ovary in humans.  These case reports provide proof of concept of the technical feasibility of the surgical procedure.

    4.2. Whole ovary removal with a view to cryopreservation

    Jadoul et al. (2007) demonstrated the feasibility of using a laparoscopic approach to harvest whole ovaries for further cryopreservation from nine patients [5]. This method maintains the minimally invasive nature of the procedure and should be the technique of choice for whole ovary cryopreservation. The authors stressed the importance of taking great care with dissection of the lumbo-ovarian ligament to ensure maximum length of the ovarian vessels (>5 cm), allowing dissection of the ovarian pedicle containing vessels of a suitable diameter (~1 mm), perfusion of the ovarian artery with cryoprotective solution, cryopreservation, and subsequent autotransplantation of the whole ovary. They also underlined the need to limit the interval between clamping of the ovarian pedicle and cryopreservation, in order to keep warm ischemia time as short as possible.

    4.3. Cryopreservation of the human ovary

    Few teams have had the opportunity to attempt cryopreservation of a whole human ovary (Table 4). Martinez-Madrid et al. (2004, 2007) were the first to report a successful slow-freezing protocol for human ovaries [83][84]. Although a significant decrease in the proportion of viable follicles (~30%) was observed after thawing, the authors did not detect any induction of apoptosis in any cell type, and no ultrastructural alterations were encountered.

    Another team subsequently proposed a second protocol for slow freezing of the human ovary based on their results from cow ovaries [9]. In this protocol, the freezing medium used was the same, but the perfusion/submersion duration was 12 times longer than in Martinez-Madrid’s protocol. The authors obtained over 90% of morphologically normal follicles after thawing. Glucose uptake in cultured tissue fragments from cryopreserved ovaries reached 90-100% of that in fresh controls, and the endothelial lining appeared undamaged. However, no comparative study was conducted to identify the most adapted protocol.

    Patrizio et al. (2007, 2008) were the first to describe successful cryopreservation of 11 human premenopausal ovaries using the directional freezing technique [85][86]. Their results were very encouraging, with no histological differences identified after thawing compared to fresh control ovaries.

    The major issue when working with premenopausal whole human ovaries is their availability. In order to facilitate further research into development of an optimal freezing/thawing protocol, Milenkovic et al. (2011b) proposed using postmenopausal ovaries [87]. Indeed, this would initially allow us to establish and improve cryopreservation protocols respecting the vasculature and stromal architecture of the human ovary, since postmenopausal ovaries are free of follicles. These selected protocols could then be applied to precious premenopausal ovaries in order to study their impact on follicle populations. Indeed, the first step to clinical application is development of an optimal freezing/thawing protocol for the human ovary. Once this goal is met, we may potentially move towards transplantation experiments performed by experts in microsurgery.

    Table 4. Cryopreservation protocols applied to human ovaries



    Freezing method

    Investigated outcomes

    Martinez-Madrid et al. 2004[83], 2007[84]


    Slow freezing

    Follicular, stromal and vascular viability, histological morphology, apoptosis, ultrastructural assessment

    Patrizio et al. 2007[85], 2008[86]


    Directional freezing

    Apoptosis, histological morphology

    Milenkovic et al. 2011b[87]

    10 (postmenopausal ovaries)

    Slow freezing

    Histological morphology, ultrastructural assessment, androgen production during in vitro perfusion

    Westphal et al. 2017[9]


    Slow freezing

    Follicular and vascular viability, histological morphology, glucose uptake during tissue fragment culture

    4.4. Recipient pedicle selection for vascular transplantation

    Studies have investigated which recipient vessels should preferably be used to enhance the success rates of microvascular anastomosis. The choice of recipient pedicle should meet the following criteria [6][12]: (i) easy surgical accessibility of the pedicle; (ii) optimal vessel size match between recipient and donor ovarian vessels; (iii) possibility of postoperative ultrasound monitoring; and (iv) easy oocyte pick-up from the transplant for in vitro fertilization. To enable orthotopic reimplantation (in an intraperitoneal grafting site) of the whole organ, the deep circumflex iliac vessels and deep inferior epigastric vessels have been proposed as potential candidates [12]. Based on anatomical evaluation of these two pedicles in 14 human female cadavers, the deep circumflex iliac vessels appeared to provide the best ovarian vessel size match to ensure reliable end-to-end vascular anastomosis. In fact, there was an optimal size match between these two pedicles in 13 out of 14 female cadavers [6]. The deep inferior epigastric vessels, on the other hand, are subject to variations. Their caliber varies along their course and their diameter gradually decreases until they enter the muscle, making them unreliable for successful anastomosis [6]. A freshly dissected contralateral ovarian pedicle may also be used, as described by Silber et al. (2008) [14], but the ovarian artery has a highly tortuous appearance [6]. When heterotopic transplantation is planned, both the cutaneous mammary branches and the antecubital vessels appear to fulfill the above-mentioned criteria [12].

    5. Limitations

    There are two inherent risks in whole ovary cryopreservation and transplantation, the first being the all-or-nothing nature of the procedure. Indeed, if any calamity occurs during the intervention, it results in loss of all the follicles present in the ovary, as opposed to use of cortical strips, where several attempts can be made with the remaining frozen fragments. The greatest risks in this instance are cryopreservation issues and clot formation during autotransplantation. Although Campbell et al. (2014) recently demonstrated a very effective freezing procedure and anti-thrombotic strategy in sheep [2], protocols still need be adjusted to human beings.

    The second crucial issue is the risk of malignant cell reimplantation [88][89][90]. While this threat also exists when transplanting frozen-thawed cortical strips, it is possible that the risk is higher when transplanting cryopreserved whole ovaries because the amount of grafted tissue is greater. An ovarian biopsy should therefore be frozen separately from the whole ovary in order to allow preimplantation analysis using extremely sensitive techniques and disease-specific markers, as done prior to cortical strip transplantation [91]. Among available techniques, histology and immunohistochemistry are sensitive enough to discern clusters of malignant cells, but isolated malignant cells may not be detected and potentially cause disease transmission upon transplantation [89][90][91]. Highly sensitive molecular biology techniques like RT-PCR are also used. They are able to identify small quantities of genetic material, whose sequences may correlate with known cancerous drifts. However, a positive result will only confirm the presence of malignant cells, but we still do not know how many malignant cells can actually cause disease recurrence [89][90][91]. Long-term xenografting experiments are nevertheless a valuable model to evaluate the risk of possible relapse. Xenotransplantation is usually performed in immunocompromised mice that serve as biological incubators, where potentially malignant cells within transplanted ovarian tissue are able to disseminate upon grafting. At degrafting, the transplants are subjected to the previously described sensitive tests and the animal is inspected for possible metastatic foci [89][90][91]. It is paramount for clinicians to bear in mind that ovarian biopsies used to perform all these tests cannot be transplanted to patients. Indeed, it is not possible to firmly rule out the presence of malignant cells in ovarian fragments that are transferred to patients.   

    If the risk of transmitting malignant cells is confirmed by preimplantation testing, one hypothetical option among others is use of the whole ovary as an ex vivo source of high-quality follicles [92][93]. Indeed, the whole ovary can be perfused in in vitro trays, and hormone stimulation and oocyte pick-up can then be performed ex vivo. In the early 1970s, researchers were able to maintain the premenopausal human ovary in perfusion for up to 8 hours and induce ovulation 4 to 5 hours after stimulation [94]. Later, rodent ovaries were perfused for up to 20 hours, allowing detailed studies into ovulation mechanisms and gonadotropin responses [95][96][97][98][99][100][101][102][103][104]. However, these periods are considerably shorter than those required to retrieve a sufficient number of mature oocytes upon ovarian stimulation in order to achieve reasonable live birth rates [105]. Pig and cow ovaries can be perfused for up to 2 days while maintaining low cellular apoptosis rates during culture [106][107], and researchers were recently able to extend the duration of whole organ culture to 4 days using fresh and frozen-thawed intact sheep ovaries [108]. Of course, further developments are required to accomplish entirely ex vivo ovarian stimulation with a view to in vitro fertilization.

    6. Conclusions

    Whole ovary cryopreservation has been proposed as an alternative method that could extend the longevity of ovarian transplants, since the entire follicle pool would be transplanted and ischemic damage to the grafted ovary would be largely avoided thanks to vascular anastomosis. This review summarizes the challenges of this technique and examines various solutions proposed in the literature over the past 20 years.

    Recent studies in the field have yielded very encouraging results and research efforts must be sustained [2][9][108]. As the permeability of any vascular anastomosis is critical to the outcome, teams investigating whole ovary transplantation should include experts with microsurgical skills. Furthermore, underlying mechanisms leading to follicle loss after transplantation of cryopreserved whole ovaries, even when vascular patency is maintained, need to be elucidated in order to develop innocuous freezing and grafting protocols. Finally, cryopreservation protocols must be adapted to human ovaries. Given their scant availability, initial studies could be conducted with postmenopausal ovaries, as proposed by Milenkovic et al. (2011b) [87].

    The entry is from 10.3390/jcm9103196


    1. David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G. Altman; The PRISMA Group; Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine 2009, 6, e1000097, 10.1371/journal.pmed.1000097.
    2. B. K. Campbell; J. Hernandez-Medrano; V. Onions; C. Pincott-Allen; F. Aljaser; J. Fisher; A. S. McNeilly; R. Webb; H. M. Picton; Restoration of ovarian function and natural fertility following the cryopreservation and autotransplantation of whole adult sheep ovaries. Human Reproduction 2014, 29, 1749-1763, 10.1093/humrep/deu144.
    3. Martin Imhof; Helga Bergmeister; Markus Lipovac; Margaretha Rudas; Gerda Hofstetter; Johannes Huber; Orthotopic microvascular reanastomosis of whole cryopreserved ovine ovaries resulting in pregnancy and live birth. Fertility and Sterility 2006, 85, 1208-1215, 10.1016/j.fertnstert.2005.11.030.
    4. Antoine Torre; Delphine Vertu-Ciolino; Claire Mazoyer; Jacqueline Selva; Jacqueline Lornage; Bruno Salle; Safeguarding Fertility With Whole Ovary Cryopreservation and Microvascular Transplantation. Transplantation 2016, 100, 1889-1897, 10.1097/tp.0000000000001296.
    5. Pascale Jadoul; Jacques Donnez; Marie-Madeleine Dolmans; Jean Squifflet; Benoît Lengele; Belen Martinez-Madrid; Laparoscopic ovariectomy for whole human ovary cryopreservation: technical aspects. Fertility and Sterility 2007, 87, 971-975, 10.1016/j.fertnstert.2006.10.012.
    6. Stéphane Ploteau; Jean-Michel Rogez; Jacques Donnez; Benoît Lengelé; Which are the ideal donor and recipient vessels for a whole ovarian transplantation?. Fertility and Sterility 2011, 95, 751-755, 10.1016/j.fertnstert.2010.07.1049.
    7. V. Isachenko; D. Peters; P. Mallmann; B. Morgenstern; E. Kellerwessel; M. Otarbaev; S. Baikoshkarova; T. Shalakhmetova; G. Rahimi; In vitro Perfusion of Whole Bovine Ovaries by Freezing Medium: Effect of Perfusion Rate and Elapsed Time after Extraction. Clinical Laboratory 2013, 59, 1159-66, 10.7754/clin.lab.2013.130635.
    8. 45. Isachenko, V.; Isachenko, E.; Sanchez, R.; Dattena, M.; Mallmann, P.; Rahimi, G; Cryopreservation of Whole Ovine Ovaries with Pedicles as a Model for Human: Parameters of Perfusion with Simultaneous Saturations by Cryoprotectants. Clinical Laboratory 2015, 61, 415-420, 10.7754/clin.lab.2014.140919.
    9. Johan R. Westphal; R. Gerritse; Didi D. M. Braat; Catharina C. M. Beerendonk; Ronald Peek; Complete protection against cryodamage of cryopreserved whole bovine and human ovaries using DMSO as a cryoprotectant. Journal of Assisted Reproduction and Genetics 2017, 34, 1217-1229, 10.1007/s10815-017-0963-x.
    10. Elisabeth Jeremias; Heterotopic autotransplantation of the ovary with microvascular anastomosis: a novel surgical technique. Fertility and Sterility 2002, 77, 1278-1282, 10.1016/s0015-0282(02)03110-2.
    11. Mohamed A. Bedaiwy; Elisabeth Jeremias; Raffi Gurunluoglu; Mahmoud R. Hussein; Maria Siemianow; Charles Biscotti; Tommaso Falcone; Restoration of ovarian function after autotransplantation of intact frozen-thawed sheep ovaries with microvascular anastomosis. Fertility and Sterility 2003, 79, 594-602, 10.1016/s0015-0282(02)04842-2.
    12. Mohamed A Bedaiwy; Tommaso Falcone; Harvesting and autotransplantation of vascularized ovarian grafts: approaches and techniques. Reproductive BioMedicine Online 2007, 14, 360-371, 10.1016/s1472-6483(10)60880-2.
    13. Anna T Grazul-Bilska; Jashoman Banerjee; Ilker Yazici; Ewa Borowczyk; Jerzy J Bilski; Rakesh K Sharma; Maria Siemionov; Tommaso Falcone; Morphology and function of cryopreserved whole ovine ovaries after heterotopic autotransplantation. Reproductive Biology and Endocrinology 2008, 6, 16-15, 10.1186/1477-7827-6-16.
    14. Sherman J. Silber; Gedis Grudzinskas; Roger G. Gosden; Successful Pregnancy after Microsurgical Transplantation of an Intact Ovary. New England Journal of Medicine 2008, 359, 2617-2618, 10.1056/nejmc0804321.
    15. Gregory M. Fahy; Brian Wowk; Jun Wu; Cryopreservation of Complex Systems: The Missing Link in the Regenerative Medicine Supply Chain. Rejuvenation Research 2006, 9, 279-291, 10.1089/rej.2006.9.279.
    16. Erik J Woods; James D Benson; Yuksel Agca; John K Critser; Fundamental cryobiology of reproductive cells and tissues. Cryobiology 2004, 48, 146-156, 10.1016/j.cryobiol.2004.03.002.
    17. H. Gacitua; Amir Arav; Successful pregnancies with directional freezing of large volume buck semen. Theriogenology 2005, 63, 931-938, 10.1016/j.theriogenology.2004.05.012.
    18. David E. Pegg; Principles of Cryopreservation. Methods in Molecular Biology 2007, 368, 39-57, 10.1007/978-1-59745-362-2_3.
    19. Zohar Gavish; Menachem Ben-Haim; Amir Arav; Cryopreservation of Whole Murine and Porcine Livers. Rejuvenation Research 2008, 11, 765-772, 10.1089/rej.2008.0706.
    20. Amir Arav; Yehudit Natan; Directional Freezing: A Solution to the Methodological Challenges to Preserve Large Organs. Seminars in Reproductive Medicine 2009, 27, 438-442, 10.1055/s-0029-1241052.
    21. Bote G. Bruinsma; Korkut Uygun; Subzero organ preservation. Current Opinion in Organ Transplantation 2017, 22, 281-286, 10.1097/mot.0000000000000403.
    22. Erik B. Finger; John Bischof; Cryopreservation by vitrification. Current Opinion in Organ Transplantation 2018, 23, 353-360, 10.1097/mot.0000000000000534.
    23. M. Imhof; G. Hofstetter; L H Bergmeister; M. Rudas; R. Kain; M. Lipovac; J. Huber; Cryopreservation of a Whole Ovary As a Strategy for Restoring Ovarian Function. Journal of Assisted Reproduction and Genetics 2004, 21, 459-465, 10.1007/s10815-004-8763-5.
    24. Ann Wallin; Manda Ghahremani; Pernilla Dahm-Kähler; Mats Brännström; Viability and function of the cryopreserved whole ovary: in vitro studies in the sheep. Human Reproduction 2009, 24, 1684-1694, 10.1093/humrep/dep060.
    25. Milan Milenkovic; Ann Wallin; Manda Ghahremani; Mats Brännström; Whole sheep ovary cryopreservation: evaluation of a slow freezing protocol with dimethylsulphoxide. Journal of Assisted Reproduction and Genetics 2010, 28, 7-14, 10.1007/s10815-010-9477-5.
    26. B. Rubinsky; D. E. Pegg; A mathematical model for the freezing process in biological tissue. Proceedings of the Royal Society of London. Series B - Biological Sciences 1988, 234, 343-358, 10.1098/rspb.1988.0053.
    27. Mats Brännström; César Díaz-García; Transplantation of female genital organs. Journal of Obstetrics and Gynaecology Research 2011, 37, 271-291, 10.1111/j.1447-0756.2010.01416.x.
    28. David E. Pegg; The relevance of ice crystal formation for the cryopreservation of tissues and organs. Cryobiology 2020, 93, 3-11, 10.1016/j.cryobiol.2020.01.005.
    29. Shijie Qi; Anlun Ma; Dasheng Xu; Pierre Daloze; Huifang Chen; Cryopreservation of vascularized ovary: An evaluation of histology and function in rats. Microsurgery 2008, 28, 380-386, 10.1002/micr.20516.
    30. Blandine Courbiere; Ludovic Caquant; Claire Mazoyer; Michel Franck; Jacqueline Lornage; Bruno Salle; Difficulties improving ovarian functional recovery by microvascular transplantation and whole ovary vitrification. Fertility and Sterility 2009, 91, 2697-2706, 10.1016/j.fertnstert.2008.03.012.
    31. V.J. Onions; R. Webb; A.S. McNeilly; B.K. Campbell; Ovarian endocrine profile and long-term vascular patency following heterotopic autotransplantation of cryopreserved whole ovine ovaries. Human Reproduction 2009, 24, 2845-2855, 10.1093/humrep/dep274.
    32. Gregory M Fahy; Brian Wowk; Jun Wu; John Phan; Chris Rasch; Alice Chang; Eric Zendejas; Cryopreservation of organs by vitrification: perspectives and recent advances. Cryobiology 2004, 48, 157-178, 10.1016/j.cryobiol.2004.02.002.
    33. Blandine Courbiere; Valentina Odagescu; A. Baudot; Jérôme Massardier; Claire Mazoyer; Bruno Salle; Jacqueline Lornage; Cryopreservation of the ovary by vitrification as an alternative to slow-cooling protocols. Fertility and Sterility 2006, 86, 1243-1251, 10.1016/j.fertnstert.2006.05.019.
    34. A. Baudot; B. Courbiere; V. Odagescu; B. Salle; C. Mazoyer; J. Massardier; Jacqueline Lornage; Towards whole sheep ovary cryopreservation. Cryobiology 2007, 55, 236-248, 10.1016/j.cryobiol.2007.08.004.
    35. R. Gerritse; C.C.M. Beerendonk; M.S.L. Tijink; A. Heetkamp; J.A.M. Kremer; D.D.M. Braat; J.R. Westphal; Optimal perfusion of an intact ovary as a prerequisite for successful ovarian cryopreservation. Human Reproduction 2007, 23, 329-335, 10.1093/humrep/dem384.
    36. A. Torre; F. Ben Brahim; T. Popowski; R. Boudjenah; B. Salle; J. Lornage; Factors related to unstained areas in whole ewe ovaries perfused with a metabolic marker. Human Reproduction 2012, 28, 423-429, 10.1093/humrep/des390.
    37. R. Gerritse; C. C. Beerendonk; J.R. Westphal; L. Bastings; D.D.M. Braat; R Peek; Glucose/lactate metabolism of cryopreserved intact bovine ovaries as a novel quantitative marker to assess tissue cryodamage. Reproductive BioMedicine Online 2011, 23, 755-764, 10.1016/j.rbmo.2011.08.008.
    38. Vladimir Isachenko; Gohar Rahimi; Maria Dattena; Peter Mallmann; Saltanat Baikoshkarova; Elisabeth Kellerwessel; Marat Otarbaev; Tamara Shalakhmetova; Evgenia Isachenko; Whole Ovine Ovaries as a Model for Human: Perfusion with CryoprotectantsIn VivoandIn Vitro. BioMed Research International 2014, 2014, 1-7, 10.1155/2014/409019.
    39. D.E. Pegg; Perfusion of rabbit kidneys with cryoprotective agents. Cryobiology 1972, 9, 411-419, 10.1016/0011-2240(72)90158-7.
    40. Blandine Courbiere; Jérôme Massardier; Bruno Salle; Claire Mazoyer; Jean-François Guérin; Jacqueline Lornage; Follicular viability and histological assessment after cryopreservation of whole sheep ovaries with vascular pedicle by vitrification. Fertility and Sterility 2005, 84, 1065-1071, 10.1016/j.fertnstert.2005.03.079.
    41. V. J. Onions; R. Webb; C. Pincott-Allen; H. M. Picton; B. K. Campbell; The effects of whole ovarian perfusion and cryopreservation on endothelial cell-related gene expression in the ovarian medulla and pedicle. MHR: Basic science of reproductive medicine 2012, 19, 205-215, 10.1093/molehr/gas053.
    42. V.J. Onions; M.R.P. Mitchell; B.K. Campbell; R. Webb; Ovarian tissue viability following whole ovine ovary cryopreservation: assessing the effects of sphingosine-1-phosphate inclusion. Human Reproduction 2008, 23, 606-618, 10.1093/humrep/dem414.
    43. C S Munn; L C Kiser; S M Wetzner; J E Baer; Ovary volume in young and premenopausal adults: US determination. Work in progress.. Radiology 1986, 159, 731-732, 10.1148/radiology.159.3.3517957.
    44. J R Scott; M Hendrickson; S Lash; J Shelby; Pregnancy after tubo-ovarian transplantation.. Obstetrics & Gynecology 1987, 70, 229-234, .
    45. Xiang Wang; Kupa K. Bilolo; Shijie Qi; Dasheng Xu; Wenlei Jiang; Minh Diem Vu; Huifang Chen; Restoration of fertility in oophorectomized rats after tubo-ovarian transplantation.. Microsurgery 2002, 22, 30-33, 10.1002/micr.22006.
    46. Yan Ding; Jialiang Shao; Keqin Hua; Xiang Wang; Modified Model of Whole Ovary Transplantation in Rats. Transplantation Proceedings 2018, 50, 3881-3886, 10.1016/j.transproceed.2018.06.038.
    47. R.M.L. Winston; J.C. Mcclure Browne; PREGNANCY FOLLOWING AUTOGRAFT TRANSPLANTATION OF FALLOPIAN TUBE AND OVARY IN THE RABBIT. The Lancet 1974, 304, 494-495, 10.1016/s0140-6736(74)92018-2.
    48. C. J. Green; S. Simpkin; G. Grimaldi; A. Johnson; Pregnancy after autografting and allografting vascularized ovaries and en bloc vascularized ovaries with adnexa in rabbits. BJOG: An International Journal of Obstetrics and Gynaecology 1982, 89, 645-651, 10.1111/j.1471-0528.1982.tb04720.x.
    49. R. Denjean; W. Boeckx; S. Gordts; I. Brosens; Ovarian transplantation by selective microvascular anastomoses in the rabbit. BJOG: An International Journal of Obstetrics and Gynaecology 1982, 89, 652-656, 10.1111/j.1471-0528.1982.tb04721.x.
    50. Hatham A. Al Chalabi; Allotransplantation of the rabbit ovary: Experimental observations and their clinical relevance. Journal of Obstetrics and Gynaecology 1991, 11, 137-144, 10.3109/01443619109013539.
    51. F. Carmona; Juan Balasch; Jesús González-Merlo; Ovarian function, tubal viability and pregnancy after tubo-ovarian transplantation in the rabbit. Human Reproduction 1993, 8, 929-931, 10.1093/oxfordjournals.humrep.a138169.
    52. Manuel M. Meraz; C.M. Revilla; C.J.C. Martı́nez; S. Islas-Andrade; E.M. Aburto; Restoration of Endocrine Function and Fertility With a Tubo-Ovarian Autotransplant as the Anatomical-Functional Unit in Rabbits Using a Vascular Microsurgical Technique. Transplantation Proceedings 2006, 38, 945-951, 10.1016/j.transproceed.2006.02.041.
    53. Manuel M. Meraz; J L Melchor; J L Melchor; C.M. Revilla; N. De Buen; E.M. Aburto; Restoration of Endocrine Function and Ovulation After a Heterotopic Ovarian Transplant in the Inguinal Region of Rabbits Using a Vascular Microsurgical Technique. Transplantation Proceedings 2006, 38, 952-957, 10.1016/j.transproceed.2006.02.043.
    54. Manuel M. Meraz; Carmen Gracida Juárez; Cristina Revilla Monsalve; Juan Carlos Martínez-Chequer; Jesús Macias Duvignau; Enrique M. Aburto Fernández; Salvador Montoya; Eduardo Tena Betancour; Restoration of Endocrine Function and Fertility with Orthotopic Tubal—Ovarian Allotransplant as the Anatomical-Functional Unit in Rabbits. Journal of Investigative Surgery 2008, 21, 348-359, 10.1080/08941930802438930.
    55. Shuangshuang Xie; Xing Zhang; Wenming Chen; Chichi Xie; Wenwei Chen; Pu Cheng; Ying Zhou; Bicheng Chen; Developmental Status: Impact of Short-Term Ischemia on Follicular Survival of Whole Ovarian Transplantation in a Rabbit Model. PLOS ONE 2015, 10, e0135049, 10.1371/journal.pone.0135049.
    56. J. R. Goding; J. A. McCracken; D. T. Baird; THE STUDY OF OVARIAN FUNCTION IN THE EWE BY MEANS OF A VASCULAR AUTOTRANSPLANTATION TECHNIQUE. Journal of Endocrinology 1967, 39, 37-52, 10.1677/joe.0.0390037.
    57. J. R. Goding; D. T. Baird; I. A. Cumming; J. A. McCracken; FUNCTIONAL ASSESSMENT OF AUTOTRANSPLANTED ENDOCRINE ORGANS. Acta Endocrinologica 1972, 68, S169-S199, 10.1530/acta.0.069s169.
    58. Carlos J.H. Souza; B K Campbell; D T Baird; Follicular Dynamics and Ovarian Steroid Secretion in Sheep during the Follicular and Early Luteal Phases of the Estrous Cycle1. Biology of Reproduction 1997, 56, 483-488, 10.1095/biolreprod56.2.483.
    59. B.K. Campbell; G. E. Mann; Alan S. McNeilly; D. T. Baird; The Pattern of Ovarian Inhibin, Estradiol, and Androstenedione Secretion during the Estrous Cycle of the Ewe*. Endocrinology 1990, 127, 227-235, 10.1210/endo-127-1-227.
    60. B. K. Campbell; H. Dobson; D. T. Baird; R. J. Scaramuzzi; Examination of the relative role of FSH and LH in the mechanism of ovulatory follicle selection in sheep. Reproduction 1999, 117, 355-367, 10.1530/jrf.0.1170355.
    61. B.K. Campbell; N.R. Kendall; D.T. Baird; The Effect of the Presence and Pattern of Luteinizing Hormone Stimulation on Ovulatory Follicle Development in Sheep1. Biology of Reproduction 2007, 76, 719-727, 10.1095/biolreprod.106.053462.
    62. Caiza A. Wranning; J. Marcickiewicz; A. Enskog; P. Dahm-Kahler; A. Hanafy; M. Brannstrom; Fertility after autologous ovine uterine-tubal-ovarian transplantation by vascular anastomosis to the external iliac vessels. Human Reproduction 2010, 25, 1973-1979, 10.1093/humrep/deq130.
    63. F A Harrison; R B Heap; Ovarian activity in a pig after autotransplantation of an ovary.. The Journal of Physiology 1972, 226, 39P, .
    64. F. A. Harrison; REPRODUCTIVE BEHAVIOUR IN THE PIG AFTER AUTOTRANSPLANTATION OF THE OVARY BY VASCULAR ANASTOMOSES. Quarterly Journal of Experimental Physiology 1982, 67, 663-670, 10.1113/expphysiol.1982.sp002685.
    65. E Paldi; D Gal; A Barzilai; N Hampel; E Malberger; Genital organs. Auto and homotransplantation in forty dogs.. International journal of fertility 1975, 20, 5-12, .
    66. James R. Scott; William R. Keye; A. Marsh Poulson; W. Ann Reynolds; Microsurgical ovarian transplantation in the primate. Fertility and Sterility 1981, 36, 512-515, 10.1016/s0015-0282(16)45803-6.
    67. Liza Johannesson; A. Enskog; P. Dahm-Kahler; A. Hanafy; D. C. Chai; J. M. Mwenda; C. Diaz-Garcia; M. Olausson; M. Brannstrom; Uterus transplantation in a non-human primate: long-term follow-up after autologous transplantation. Human Reproduction 2012, 27, 1640-1648, 10.1093/humrep/des093.
    68. Xiang Wang; Huifang Chen; Hang Yin; S. Samuel Kim; Seang Lin Tan; Roger G. Gosden; Fertility after intact ovary transplantation. Nature 2002, 415, 385-385, 10.1038/415385a.
    69. Hang Yin; Xiang Wang; S.Samuel Kim; Huifang Chen; Seang Lin Tan; Roger G. Gosden; Transplantation of intact rat gonads using vascular anastomosis: effects of cryopreservation, ischaemia and genotype. Human Reproduction 2003, 18, 1165-1172, 10.1093/humrep/deg236.
    70. Yan Ding; Jia-Liang Shao; Jun-Wei Li; Ying Zhang; Kai-Hua Hong; Ke-Qin Hua; Xiang Wang; Successful fertility following optimized perfusion and cryopreservation of whole ovary and allotransplantation in a premature ovarian insufficiency rat model. Journal of Ovarian Research 2018, 11, 35, 10.1186/s13048-018-0401-4.
    71. Chi-Huang Chen; Shyi-Gen Chen; Gwo-Jang Wu; Jaang Wang; Cheng-Ping Yu; Jah-Yao Liu; Autologous heterotopic transplantation of intact rabbit ovary after frozen banking at −196°C. Fertility and Sterility 2006, 86, 1059-1066, 10.1016/j.fertnstert.2006.04.019.
    72. A. Arav; A. Revel; Y. Nathan; A. Bor; H. Gacitua; S. Yavin; Z. Gavish; M. Uri; A. Elami; Oocyte recovery, embryo development and ovarian function after cryopreservation and transplantation of whole sheep ovary. Human Reproduction 2005, 20, 3554-3559, 10.1093/humrep/dei278.
    73. Amir Arav; Z. Gavish; A. Elami; Y. Natan; A. Revel; S. Silber; R.G. Gosden; P. Patrizio; Ovarian function 6years after cryopreservation and transplantation of whole sheep ovaries. Reproductive BioMedicine Online 2010, 20, 48-52, 10.1016/j.rbmo.2009.10.019.
    74. Ariel Revel; Amir Elami; Amir Bor; Saar Yavin; Yehudit Natan; Amir Arav; Whole sheep ovary cryopreservation and transplantation. Fertility and Sterility 2004, 82, 1714-1715, 10.1016/j.fertnstert.2004.06.046.
    75. Michel Leporrier; Peter Von Theobald; Jean-Luc Roffe; Georges Muller; A new technique to protect ovarian function before pelvic irradiation: Heterotopic ovarian autotransplantation. Cancer 1987, 60, 2201-2204, 10.1002/1097-0142(19871101)60:9<2201::aid-cncr2820600915>;2-z.
    76. Carina G. Hilders; Andrzej G. Baranski; Lex Peters; Andre Ramkhelawan; J. Baptist Trimbos; Successful human ovarian autotransplantation to the upper arm. Cancer 2004, 101, 2771-2778, 10.1002/cncr.20715.
    77. P. Mhatre; J. Mhatre; R. Magotra; Ovarian Transplant: A New Frontier. Transplantation Proceedings 2005, 37, 1396-1398, 10.1016/j.transproceed.2004.11.083.
    78. Homero López‐Monjardin; J. Abel De La Peña‐Salcedo; Techniques for management of size discrepancies in microvascular anastomosis. Microsurgery 2000, 20, 162-166, 10.1002/1098-2752(2000)20:4<162::aid-micr3>;2-l.
    79. Tolga Turker; Tsu-Min Tsai; Sunil Thirkannad; SIZE DISCREPANCY IN VESSELS DURING MICROVASCULAR ANASTOMOSIS: TWO TECHNIQUES TO OVERCOME THIS PROBLEM. Hand Surgery 2012, 17, 413-417, 10.1142/s0218810412970052.
    80. 137. Mohammad, M.; Adjei, B.; George, S.; Alfeky, H.; Mostafa, A.; Dimovelis, I.; El-Gawad, A.; Microsurgery and Vessel Caliber Mismatch: A Review of Microsurgery Anastomosis Techniques to Overcome Vessel Diameter Discrepancy. Journal of Orthoplastic Surgery 2020, 3, 87-95, .
    81. C. J. Zeebregts; R. H. Heijmen; J. J. Van Den Dungen; R. Van Schilfgaarde; Non-suture methods of vascular anastomosis. British Journal of Surgery 2003, 90, 261-271, 10.1002/bjs.4063.
    82. Vlad Ilie; Roger Haddad; Elias Moisidis; Sutureless Microvascular Anastomosis: Literature Review. International Microsurgery Journal 2019, 3, 1, 10.24983/scitemed.imj.2019.00112.
    83. Belen Martinez-Madrid; Marie-Madeleine Dolmans; Anne Van Langendonckt; Sylvie Defrère; Jacques Donnez; Freeze-thawing intact human ovary with its vascular pedicle with a passive cooling device. Fertility and Sterility 2004, 82, 1390-1394, 10.1016/j.fertnstert.2004.06.036.
    84. Belen Martinez-Madrid; Alessandra Camboni; Marie-Madeleine Dolmans; Stefania Annarita Nottola; Anne Van Langendonckt; Jacques Donnez; Apoptosis and ultrastructural assessment after cryopreservation of whole human ovaries with their vascular pedicle. Fertility and Sterility 2007, 87, 1153-1165, 10.1016/j.fertnstert.2006.11.019.
    85. P. Patrizio; Z. Gavish; M. Martel; M. Azodi; S. Silber; A. Arav; Whole human ovaries cryopreservation using a novel multi-gradient freezing device. Fertility and Sterility 2007, 88, S355, 10.1016/j.fertnstert.2007.07.1192.
    86. P. Patrizio; J. Bromer; J. Johnson; M. Martel; S. Silber; A. Arav; Cryopreservation of eleven whole human ovaries: histology, immunohistochemistry and technical details. Fertility and Sterility 2008, 90, S38-S38, 10.1016/j.fertnstert.2008.07.620.
    87. Milan Milenkovic; Manda Gharemani; Anette Bergh; Ann Wallin; Johan Mölne; Elvedin Fazlagic; Eirik Eliassen; Jarl Kahn; Mats Brännström; The human postmenopausal ovary as a tool for evaluation of cryopreservation protocols towards whole ovary cryopreservation. Journal of Assisted Reproduction and Genetics 2011, 28, 453-460, 10.1007/s10815-011-9547-3.
    88. W Hamish B Wallace; Richard A Anderson; D Stewart Irvine; Fertility preservation for young patients with cancer: who is at risk and what can be offered?. The Lancet Oncology 2005, 6, 209-218, 10.1016/s1470-2045(05)70092-9.
    89. Marie-Madeleine Dolmans; Valérie Luyckx; Jacques Donnez; Claus Yding Andersen; Tine Greve; Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertility and Sterility 2013, 99, 1514-1522, 10.1016/j.fertnstert.2013.03.027.
    90. Mikkel Rosendahl; Tine Greve; Claus Yding Andersen; The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. Journal of Assisted Reproduction and Genetics 2012, 30, 11-24, 10.1007/s10815-012-9912-x.
    91. 144. Dolmans, M.M.; Masciangelo, R.; Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Minerva Ginecologica 2018, 70, 436-443, 10.23736/S0026-4784.18.04233-8.
    92. Julie Vanacker; Valérie Luyckx; Christiani Amorim; Marie-Madeleine Dolmans; Anne Van Langendonckt; J. Donnez; Alessandra Camboni; Should we isolate human preantral follicles before or after cryopreservation of ovarian tissue?. Fertility and Sterility 2013, 99, 1363-1368.e2, 10.1016/j.fertnstert.2012.12.016.
    93. Jacques Donnez; Marie‐Madeleine Dolmans; Fertility Preservation in Women. New England Journal of Medicine 2017, 377, 1657-1665, 10.1056/nejmra1614676.
    94. E Stähler; L Spätling; H D Bethge; E Daume; R Buchholz; Induction of ovulation in human ovaries perfused in vitro.. null 1974, 217, 1-15, .
    95. C J Lambertsen; D F Greenbaum; K H Wright; E E Wallach; In vitro studies of ovulation in the perfused rabbit ovary.. Fertility and Sterility 1976, 27, 178-187, .
    96. Y. Hamada; R. A. Bronson; K. H. Wright; E. F. Wallach; Ovulation in the Perfused Rabbit Ovary: The Influence of Prostaglandins and Prostaglandin Inhibitors1. Biology of Reproduction 1977, 17, 58-63, 10.1095/biolreprod17.1.58.
    97. Y Hamada; K H Wright; E E Wallach; The effects of progesterone and human chorionic gonadotropin on ovulation in the in vitro perfused rabbit ovary.. Fertility and Sterility 1979, 32, 335-339, .
    98. Edward E. Wallach; Karen H. Wright; Yasuo Hamada; Investigation of mammalian ovulation with an in vitro perfused rabbit ovary preparation. American Journal of Obstetrics and Gynecology 1978, 132, 728-738, 10.1016/s0002-9378(78)80007-6.
    99. Yoshimune Kobayashi; Karen H. Wright; Rosemary Santulli; Edward E. Wallach; Ovulation and Ovum Maturation in the Rabbit Ovary Perfused in vitro. Biology of Reproduction 1981, 24, 483-490, 10.1095/biolreprod24.3.483.
    100. R. D. Koos; F. J. Jaccarino; R. A. Magaril; W. J. Le Maire; Perfusion of the Rat Ovary In Vitro: Methodology, Induction of Ovulation, and Pattern of Steroidogenesis 1. Biology of Reproduction 1984, 30, 1135-1141, 10.1095/biolreprod30.5.1135.
    101. Jan Sogn; Gun Abrahamsson; Per O. Janson; Release of cyclic AMP and progesterone from the isolated perfused luteal ovary of the PMSG treated rat. Acta Endocrinologica 1984, 106, 265-270, 10.1530/acta.0.1060265.
    102. J. H. Sogn; T. E. Curry; M. Brännström; W. J. Lemaire; R. D. Koos; H. Papkoff; P. O. Janson; Inhibition of Follicle-Stimulating Hormone-Induced Ovulation by Indomethacin in the Perfused Rat Ovary1. Biology of Reproduction 1987, 36, 536-542, 10.1095/biolreprod36.3.536.
    103. M. Brannstrom; B. M. Johansson; J. Sogn; P. O. Janson; Characterization of anin vitroperfused rat ovary model: ovulation rate, oocyte maturation, steroidogenesis and influence of PMSG priming. Acta Physiologica Scandinavica 1987, 130, 107-114, 10.1111/j.1748-1716.1987.tb08117.x.
    104. M. Brannstrom; S. Flaherty; Methodology and characterization of an in vitro perfusion model for the mouse ovary. REPRODUCTION 1995, 105, 177-183, 10.1530/jrf.0.1050177.
    105. Ana Cobo; Juan A. García-Velasco; Aila Coello; Javier Domingo; Antonio Pellicer; José Remohí; Oocyte vitrification as an efficient option for elective fertility preservation. Fertility and Sterility 2016, 105, 755-764.e8, 10.1016/j.fertnstert.2015.11.027.
    106. N. T. Werthessen; E. Schwenk; C. Baker; Biosynthesis of Estrone and beta-Estradiol in the Perfused Ovary. Science 1953, 117, 380-381, 10.1126/science.117.3041.380.
    107. Matthew R. Zanotelli; Joseph D. Henningsen; Patrick M. Hopkins; Aaron P. Dederich; Tessa Herman; Tracy J. Puccinelli; Sana M. Salih; An ovarian bioreactor for in vitro culture of the whole bovine ovary: a preliminary report. Journal of Ovarian Research 2016, 9, 1-11, 10.1186/s13048-016-0249-4.
    108. Sara Maffei; Giovanna Galeati; Georgia Pennarossa; Tiziana A. L. Brevini; F. Gandolfi; Extended ex vivo culture of fresh and cryopreserved whole sheep ovaries. Reproduction, Fertility and Development 2016, 28, 1893-1903, 10.1071/rd15101.
    1. Please check and comment entries here.